Latest Content

Care at every step is the ethical duty of nurses, says Katherine Brown-Saltzman, MA, RN, in this episode of Onc Nurse On Call.

After undergoing EBRT and brachytherapy at 14, an AYA cancer survivor discusses her experience with a rare vaginal cancer and Turner syndrome.

Catherine Boyles, RN, OCN, explains how to help patients help themselves when preparing for appointments.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, explains that later cytopenias should be monitored in patients undergoing CAR T-cell therapy.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj for use in patients with high-risk smoldering multiple myeloma.

An oncology APP-led quality assurance committee identified key safety events across disciplines and specialties.

The frontline addition of cancer vaccine IO102-IO103 to pembrolizumab demonstrated an increase in PFS in patients with advanced melanoma.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Among lymphoma survivors, a multidisciplinary intervention program had a beneficial effect on fatigue and aspects of health-related quality of life.

Twenty-year follow-up demonstrated continued imatinib efficacy in advanced GIST with doubled median overall survival.